Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
73 Leser
Artikel bewerten:
(0)

Global Influenza Drugs and Vaccines Market 2016-2021:By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir) & Vaccine (Trivalent, Quadrivalent) - Research and Markets

DUBLIN, June 2, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Influenza Drugs and Vaccines Market - By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis By Region, By Country: Opportunities and Forecast (2016-2021) - By Region, By Country" report to their offering.

Research and Markets Logo

Rising awareness in relation to influenza virus, surging investment by companies in R&D and increasing number of immunization programmes organized by the government have been some of the factors backing the growth of Global Influenza Market.

The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global influenza market. Additionally, the report also highlights key development and new drugs launched by various companies across the globe.

Scope of the Report

Global Influenza Market (Actual Period: 2012-2016E, Forecast Period: 2017-2022)

- By Segment Type: Influenza Vaccine Market, Influenza Drugs Market
- By Vaccine Type: Trivalent, Quadrivalent
- By Drug Type: Zanamivi, Oseltamivir Phosphate, Peramivir

Regional Markets - North America, Europe, APAC, RoW (Actual Period: 2012-2016E, Forecast Period: 2017-2022)

- By Segment Type: Influenza Vaccine Market, Influenza Drugs Market
- By Vaccine Type: Trivalent, Quadrivalent
- By Drug Type: Zanamivi, Oseltamivir Phosphate, Peramivir

Country Analysis - US, Canada, UK, Germany, France, Japan, China, India (Actual Period: 2012-2016E, Forecast Period: 2017-2022)

- By Segment Type: Influenza Vaccine Market, Influenza Drugs Market

Other Report Highlights

- Market Dynamics - Trends, Drivers, Challenges
- Pipeline Analysis
- Company Analysis - Falvogen, Gilead Science and Bio Cryst

Key Topics Covered:

1. Influenza Market: An Introduction

2. Global Influenza Market Overview

3. Global Influenza Market, Product Analysis

4. Global Influenza Vaccines & Drugs - Pipeline Analysis

5. Global Influenza Market, By Region

6. North America Influenza Market Overview

7. United States Influenza Market Overview

8. Europe Influenza Market Overview

9. United Kingdom Influenza Market Overview

10. France Influenza Market Overview

11. APAC Influenza Market Overview

12. India Influenza Market Overview

13. China Influenza Market Overview

14. ROW Influenza Market Overview

15. Market Dynamics

16. Company Profiles

  • Alvogen
  • Astrazeneca
  • BioCryst Pharmaceuticals.Inc.
  • CSL Limited
  • Emergent Biosolutions
  • GlaxoSmithKline
  • Protein Sciences Corporation
  • Sanofi Pasteur, Inc.
  • Serum Institute Of India Pvt. Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/kkn6wn/global_influenza

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.